Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Rheumatology

• Publication date

  1996-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 8923354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression.

  2010cited by this paper
• Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

  1995cited by this paper
• In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis.

  1993cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases.

  1988cited by this paper
• Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor- mediated action of a diphtheria toxin-related interleukin 2 fusion protein

  1988cited by this paper
• Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein.

  1987cited by this paper
• Immunologic studies of rheumatoid arthritis patients treated with methotrexate.

  1987cited by this paper
• Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

  1985cited by this paper
• In vitro IgM and IgM rheumatoid factor production and response to remittive agents in rheumatoid arthritis.

  1985cited by this paper
• Expression of interleukin 2 receptors on activated human B cells

  1984cited by this paper
• Spontaneous synthesis of IgM rheumatoid factor by blood mononuclear cells from patients with rheumatoid arthritis: effect of treatment with gold salts or D-penicillamine.

  1984cited by this paper
• IgG and IgM rheumatoid factors in rheumatoid arthritis. Quantitative response to penicillamine therapy and relationship to disease activity.

  1983cited by this paper
• In vitro synthesis of IgM rheumatoid factor by lymphocytes from healthy adults.

  1980cited by this paper
• Cellular requirements for pokeweed mitogen-induced autoantibody production rheumatoid arthritis.

  1980cited by this paper
• Enhanced in vitro synthesis of IgM rheumatoid factor in rheumatoid arthritis.

  1980cited by this paper

• COMBINATION OF PROSORBA IMMUNOADSORPTION FOLLOWED BY B- CELL DEPLETION WITH RITUXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS AN INDEPENDENT OPEN CLINCIAL TRIAL

  2017cites this paper
• Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.

  2014cites this paper
• Preclinical Immunotoxicology Assessment of Cytokine Therapeutics

  2003cites this paper
• Diphtheria fusion protein therapy of chemoresistant malignancies.

  2002cites this paper
• Potential biologic agents for treating rheumatoid arthritis.

  2001cites this paper
• Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL‐2 receptor (DACLIZUMAB) on collagen‐induced arthritis (CIA) in rhesus monkeys

  2001cites this paper
• Targeting of cells involved in the pathogenesis of rheumatoid arthritis.

  1999cites this paper
• Animal Models of Arthritis: Relevance to Human Disease

  1999cites this paper
• Management of therapy-resistant rheumatoid arthritis.

  1999cites this paper
• Rheumatoid Arthritis: Anticytokine Therapies on the Horizon

  1998cites this paper